HekeTiss has developed TrophiPatch, a cell-based skin patch utilizing adipose-derived stem cells to enhance the healing of chronic ulcers. This solution addresses the significant medical need for effective treatments for non-healing wounds, which affect over 1% of the global population.
Funding
$170K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic ulcers, resulting from conditions like diabetes and cardiovascular disorders, affect a significant portion of the global population, leading to pain, disability, and reduced quality of life. Current treatments often fail to provide adequate or accelerated healing for these non-healing wounds.
Solution
HekeTiss is developing TrophiPatch, a cell-based skin patch designed to enhance the healing of chronic ulcers. The patch utilizes adipose-derived stem cells, leveraging their angiogenic and regenerative properties to promote superior cicatrization of skin wounds. TrophiPatch offers an off-the-shelf solution aimed at addressing the unmet medical need for effective chronic ulcer treatments. Pre-clinical animal testing has been successfully completed, demonstrating safety and efficacy.
Target Audience
The primary target audience includes patients suffering from chronic ulcers due to conditions such as diabetes and cardiovascular disorders, as well as clinicians seeking advanced wound-healing solutions.
Features
- Cell-based skin patch containing adipose-derived stem cells
- Designed to promote angiogenesis and tissue regeneration in chronic wounds
- Off-the-shelf availability for immediate application
- Demonstrated safety and efficacy in pre-clinical animal studies